Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain
Name
Miller_Targeting autocrine.pdf
Size
1.06 MB
Format
Adobe PDF
Checksum (MD5)
d210074b3882eecdab26548ed3f2c5b3
Author(s) • • • • • • •
Miller, Miles Aaron
Moss, Marcia L.
Powell, Gary
Petrovich, Robert
Edwards, Lori
Griffith, Linda G.
Lauffenburger, Douglas A.
Meyer, Aaron Samuel
Date Issued
October 2015
Journal
Scientific Reports
Publisher
Nature Publishing Group
Citation
Miller, Miles A., Marcia L. Moss, Gary Powell, Robert Petrovich, Lori Edwards, Aaron S. Meyer, Linda G. Griffith, and Douglas A. Lauffenburger. “Targeting Autocrine HB-EGF Signaling with Specific ADAM12 Inhibition Using Recombinant ADAM12 Prodomain.” Scientific Reports 5 (October 19, 2015): 15150.
Version
Final published version
Abstract
Dysregulation of ErbB-family signaling underlies numerous pathologies and has been therapeutically targeted through inhibiting ErbB-receptors themselves or their cognate ligands. For the latter, “decoy” antibodies have been developed to sequester ligands including heparin-binding epidermal growth factor (HB-EGF); however, demonstrating sufficient efficacy has been difficult. Here, we hypothesized that this strategy depends on properties such as ligand-receptor binding affinity, which varies widely across the known ErbB-family ligands. Guided by computational modeling, we found that high-affinity ligands such as HB-EGF are more difficult to target with decoy antibodies compared to low-affinity ligands such as amphiregulin (AREG). To address this issue, we developed an alternative method for inhibiting HB-EGF activity by targeting its cleavage from the cell surface. In a model of the invasive disease endometriosis, we identified A Disintegrin and Metalloproteinase 12 (ADAM12) as a protease implicated in HB-EGF shedding. We designed a specific inhibitor of ADAM12 based on its recombinant prodomain (PA12), which selectively inhibits ADAM12 but not ADAM10 or ADAM17. In endometriotic cells, PA12 significantly reduced HB-EGF shedding and resultant cellular migration. Overall, specific inhibition of ligand shedding represents a possible alternative to decoy antibodies, especially for ligands such as HB-EGF that exhibit high binding affinity and localized signaling.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/srep15150